IN STRAIGHT TERMS

Strategic Business Plan: The GLP-1 Patch Project & Topical Formulations Company

1.0 Introduction: A Dual-Focus Enterprise

This document outlines the investment opportunity in a uniquely structured company that pairs a stable, revenue-generating product line with a high-growth R&D initiative, creating a de-risked pathway into the lucrative wellness market. The business is composed of two core, synergistic components: the established “Topical Company,” which is commercially active, and the new “GLP-1 Patch” project, a forward-looking development initiative. This plan details how these two divisions form a single, compelling investment opportunity, spearheaded by company principals Cliff (Bud) Lackie and Bryan Brant. We will explore the unified corporate structure that underpins this venture and the value it presents to potential investors.

2.0 Corporate Structure & Investment Synopsis

Understanding the company’s unified corporate structure is essential to appreciating the full scope of the investment opportunity. The existing topical product lines and the future GLP-1 project are not separate ventures; they are integral parts of a single corporate entity. This unified structure is intentional, providing investors with immediate participation in an operational business while funding a high-upside project. The established division serves to de-risk the venture capital component of the investment.

The investment opportunity is therefore comprehensive. Any investment confers shares in the entire company, encompassing both the topical product line and the innovative GLP-1 project.

A summary of capital investment to date highlights the company’s commitment to both its foundational and growth-oriented divisions:

• Topical Formulations: $500,000
• GLP-1 Project (R&D Stage): $100,000

This established operational base is the engine that will power our strategic growth.

3.0 Current Operations: The Topical Products Division

The Topical Company serves as the foundational pillar of the enterprise. These existing product formulations provide the operational backbone, an established market presence, and the critical distribution infrastructure essential for current and future growth. This division has already received a significant investment of $500,000 to develop its formulations and bring them to market, providing immediate, nationwide market access that would otherwise require years and significant capital to build.

This division is fully operational and is Currently In Production, solidifying its role as the commercially active component of the business. The success and infrastructure of the Topical Products Division provide a powerful platform from which to launch the company’s next exciting project.

4.0 Strategic Growth Initiative: The GLP-1 Transdermal Patch

The GLP-1 Patch is the company’s flagship innovation project, representing a strategic move to capitalize on the rapidly growing and high-demand wellness market. This initiative is designed to meet a clear and pressing consumer need with a distinct and compelling product offering. The project’s market positioning is clear and powerful:

The Natural alternative to Ozempic

This positioning strategically differentiates the product, appealing to a consumer base seeking effective, non-pharmaceutical options. The project is currently in the R&D Stage, supported by an initial investment of $100,000 dedicated to its development. The successful launch of this product will be achieved by leveraging the company’s existing assets and a well-defined go-to-market plan.

5.0 Go-to-Market Synergy & Distribution Strategy

A product’s success is defined by its go-to-market strategy. The company’s core competitive advantage lies in its ability to leverage existing operational assets for a rapid, efficient, and cost-effective product launch. This synergy between our established and developing divisions is the cornerstone of our commercialization plan.

Our primary distribution strategy constitutes a significant barrier to entry for competitors. We will leverage the fully operational distribution network of our topical products to accelerate the GLP-1 product into the market. This approach bypasses the time and expense of building new channels from scratch, granting the GLP-1 patch immediate access to established retail and consumer networks.

Furthermore, the company possesses several other strategic assets to enhance market penetration. In addition to the primary network, we have access to several other distribution circles. Comprehensive details on these valuable channels will be disclosed to serious parties upon the signing of a Non-Disclosure Agreement (NDA).

6.0 Conclusion and Invitation for Discussion

This business plan presents a unique value proposition: an investment in tangible assets and market presence, combined with the explosive potential of a wellness innovation. The synergy between the established Topical Company and the innovative GLP-1 Patch project, linked by a pre-existing distribution strategy, creates a de-risked pathway to significant growth.

We invite interested parties to contact our leadership for further questions or to proceed with an NDA to review more detailed information regarding our supplementary distribution channels and strategic plans.

• Company Principals: Cliff (Bud) Lackie, Bryan Brant
• Project Website: www.glp-1transdermalpatch.com